The role of NQO1 in ovarian cancer
G Tossetta, S Fantone, G Goteri, SR Giannubilo… - International journal of …, 2023 - mdpi.com
Ovarian cancer is one of the most dangerous gynecologic malignancies showing a high
fatality rate because of late diagnosis and relapse occurrence due to chemoresistance …
fatality rate because of late diagnosis and relapse occurrence due to chemoresistance …
NAD (P) H: quinone oxidoreductase 1 (NQO1) as a therapeutic and diagnostic target in cancer
K Zhang, D Chen, K Ma, X Wu, H Hao… - Journal of Medicinal …, 2018 - ACS Publications
NAD (P) H: quinone oxidoreductase 1 (NQO1) is a two-electron reductase responsible for
detoxification of quinones and also bioactivation of certain quinones. It is abnormally …
detoxification of quinones and also bioactivation of certain quinones. It is abnormally …
Recent advances in NAMPT inhibitors: a novel immunotherapic strategy
Nicotinamide adenine dinucleotide (NAD) is a cofactor of many enzymatic reactions as well
as being a substrate for a number of NAD-consuming enzymes (eg, PARPS, sirtuins, etc) …
as being a substrate for a number of NAD-consuming enzymes (eg, PARPS, sirtuins, etc) …
Cancer cell metabolic plasticity in migration and metastasis
JA Mosier, SC Schwager, DA Boyajian… - Clinical & experimental …, 2021 - Springer
Metabolic reprogramming is a hallmark of cancer metastasis in which cancer cells
manipulate their metabolic profile to meet the dynamic energetic requirements of the tumor …
manipulate their metabolic profile to meet the dynamic energetic requirements of the tumor …
Beyond energy metabolism: exploiting the additional roles of NAMPT for cancer therapy
CM Heske - Frontiers in oncology, 2020 - frontiersin.org
Tumor cells have increased requirements for NAD+. Thus, many cancers exhibit an
increased reliance on NAD+ production pathways. This dependence may be exploited …
increased reliance on NAD+ production pathways. This dependence may be exploited …
Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ss-lapachone
G Chakrabarti, ZR Moore, X Luo, M Ilcheva, A Ali… - Cancer & …, 2015 - Springer
Background Pancreatic ductal adenocarcinomas (PDA) activate a glutamine-dependent
pathway of cytosolic nicotinamide adenine dinucleotide phosphate (NADPH) production to …
pathway of cytosolic nicotinamide adenine dinucleotide phosphate (NADPH) production to …
Advances in NAD-lowering agents for cancer treatment
MS Ghanem, F Monacelli, A Nencioni - Nutrients, 2021 - mdpi.com
Nicotinamide adenine dinucleotide (NAD) is an essential redox cofactor, but it also acts as a
substrate for NAD-consuming enzymes, regulating cellular events such as DNA repair and …
substrate for NAD-consuming enzymes, regulating cellular events such as DNA repair and …
A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials
Q Gong, J Hu, P Wang, X Li, X Zhang - European Journal of Medicinal …, 2021 - Elsevier
Abstract β-Lapachone (β-lap, 1), an ortho-naphthoquinone natural product isolated from the
lapacho tree (Tabebuia avellanedae) in many regions of South America, has received …
lapacho tree (Tabebuia avellanedae) in many regions of South America, has received …
NAD+ salvage pathway in cancer metabolism and therapy
BE Kennedy, T Sharif, E Martell, C Dai, Y Kim… - Pharmacological …, 2016 - Elsevier
Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme for various
physiological processes including energy metabolism, DNA repair, cell growth, and cell …
physiological processes including energy metabolism, DNA repair, cell growth, and cell …
[HTML][HTML] Leveraging an NQO1 bioactivatable drug for tumor-selective use of poly (ADP-ribose) polymerase inhibitors
Therapeutic drugs that block DNA repair, including poly (ADP-ribose) polymerase (PARP)
inhibitors, fail due to lack of tumor-selectivity. When PARP inhibitors and β-lapachone are …
inhibitors, fail due to lack of tumor-selectivity. When PARP inhibitors and β-lapachone are …